Shares of the stock have been a powerhouse leader in the cannabis patch in recent action. This is one of a very, very select group that has shown genuine technical strength not simply tied to US legislative moves. The stock is on a roll and still has a ways to go before flashing worrisome levels of overbought-ness.
Trulieve Cannabis Corp (OTCMKTS:TCNNF) just announced its financial results for the third quarter of 2019 ended September 30, 2019, including record revenue of $70.7 million, an increase of 22% on a sequential quarter-to-quarter basis, and an adjusted EBITDA increase from $31.6 million in Q2 2019 to $36.9 million at September 30, 2019.
"Our third quarter results reflect our continued customer loyalty, growth, and leadership position. Trulieve's strong brand, wide-ranging access to stores, and authentic customer experience have resonated with our customers and patients," stated Kim Rivers, Trulieve CEO . "The third quarter was also successful in further strengthening our position in our existing markets as well as preparing for new market entry. We continue to build operational efficiencies and financial discipline to ensure a solid foundation, cash reserves, and the right tools at our disposal to expand our footprint. Looking ahead, this is an exciting time as we execute on our strategic vision to be one of the top performing cannabis companies in North America."
Trulieve Cannabis Corp (OTCMKTS:TCNNF) promulgates itself as a company that, through its subsidiary, Trulieve, Inc., engages in the cultivation, possession, distribution, and sale of medical cannabis in the United States.
It offers a suite of Trulieve branded products with approximately 125 SKUs, including nasal sprays, capsules, concentrates, syringes, and cannabis flower in tamper-proof containers for vaporizers, topical creams, tinctures, and vape cartridges.
Read More at: https://dailytrendingstocks.com/have-the...